Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The partnership covers the entire product lifecycle from early-stage development through commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Subscribe To Our Newsletter & Stay Updated
